Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti; P.A. Zucali; Y.G. Assaraf; L.G. Leon; K Smid; C. Alecci; F. Giancola; A. Destro; L. Gianoncelli; E. Lorenzi; M. Roncalli; A. Santoro; G.J. Peters

doi:10.1038/bjc.2011.400

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti, P.A. Zucali, Y.G. Assaraf, L.G. Leon, K Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, M. Roncalli, A. Santoro, G.J. Peters

Medical oncology laboratory

Research output: Contribution to journal › Article › Academic › peer-review

73 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	1542-1553
Journal	British Journal of Cancer
Volume	105
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2011.400
Publication status	Published - 2011

Access to Document

10.1038/bjc.2011.400

282702Final published version, 704 KB

Cite this

Giovannetti, E., Zucali, P. A., Assaraf, Y. G., Leon, L. G., Smid, K., Alecci, C., Giancola, F., Destro, A., Gianoncelli, L., Lorenzi, E., Roncalli, M., Santoro, A., & Peters, G. J. (2011). Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. British Journal of Cancer, 105(10), 1542-1553. https://doi.org/10.1038/bjc.2011.400

@article{63ddadc17af34879b61e9074f3e1d091,

title = "Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin",

author = "E. Giovannetti and P.A. Zucali and Y.G. Assaraf and L.G. Leon and K Smid and C. Alecci and F. Giancola and A. Destro and L. Gianoncelli and E. Lorenzi and M. Roncalli and A. Santoro and G.J. Peters",

year = "2011",

doi = "10.1038/bjc.2011.400",

language = "Undefined/Unknown",

volume = "105",

pages = "1542--1553",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

Giovannetti, E, Zucali, PA, Assaraf, YG, Leon, LG, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A & Peters, GJ 2011, 'Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin', British Journal of Cancer, vol. 105, no. 10, pp. 1542-1553. https://doi.org/10.1038/bjc.2011.400

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. / Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G. et al.

In: British Journal of Cancer, Vol. 105, No. 10, 2011, p. 1542-1553.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

AU - Giovannetti, E.

AU - Zucali, P.A.

AU - Assaraf, Y.G.

AU - Leon, L.G.

AU - Smid, K

AU - Alecci, C.

AU - Giancola, F.

AU - Destro, A.

AU - Gianoncelli, L.

AU - Lorenzi, E.

AU - Roncalli, M.

AU - Santoro, A.

AU - Peters, G.J.

PY - 2011

Y1 - 2011

U2 - 10.1038/bjc.2011.400

DO - 10.1038/bjc.2011.400

M3 - Article

C2 - 21970874

VL - 105

SP - 1542

EP - 1553

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -